trending Market Intelligence /marketintelligence/en/news-insights/trending/Sqnma8R5-7f0HJznIbkU6A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers' Opdivo's new dosing regimen for skin cancer approved in EU

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Bristol-Myers' Opdivo's new dosing regimen for skin cancer approved in EU

The European Commission approved a new dosing regimen for Bristol-Myers Squibb Co.'s blockbuster drug Opdivo as an add-on treatment for certain patients with a type of skin cancer.

Opdivo's flat dosing schedule of 240 milligrams infused over 30 minutes every two weeks or 480 milligrams infused over 60 minutes every four weeks can now be used as an adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or whose disease has spread to other parts and have undergone complete resection.

Melanoma is a type of skin cancer characterized by the uncontrolled growth of pigment-producing cells in the skin.

Bristol-Myers said in an Oct. 24 press release that the approval for the new dosing regimen will provide additional treatment flexibility for patients in the EU.

The drug is already approved in several countries to treat different types of cancer.